PTC Therapeutics reports FY2025 product/royalty rev $831M, beats guidance; Sephience Q4 rev $92M

PTC THERAPEUTICS, INC.

2025-FY EPS reported $7.78 revenue$1,730,655,000

Full-year 2025 product/royalty revenue $831M, exceeding guidance; total revenue $1.73B (includes $998M Novartis collaboration).
Sephience launch strong: Q4 rev $92M ($81M US), 946 patients on therapy; full-year rev $111M.
Net income $682.6M for FY2025 vs net loss $363.3M in FY2024; cash $1.95B as of Dec 31.
Sold Evrysdi royalty to Royalty Pharma for $240M upfront + up to $60M milestones; retains $150M Roche milestone.
2026 guidance: product rev $700-800M (19-36% growth); Phase 3 HD trial INVEST-HD to start 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.